SAR446268 / Sanofi - LARVOL DELTA

BrAAVe: A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1 (clinicaltrials.gov) - P1/2 | N=32 | Recruiting | Sponsor: Sanofi | Trial completion date: Feb 2029 ➔ Apr 2032

Trial completion date • Gene Therapies • Genetic Disorders • Muscular Dystrophy • Myotonic Dystrophy